Abstract
To investigate the value of radiomics analysis of dual-energy computed tomography (DECT)-derived iodine maps for preoperative diagnosing cervical lymph nodes (LNs) metastasis in patients with papillary thyroid cancer (PTC). Two hundred and fifty-five LNs (143 non-metastatic and 112 metastatic) were enrolled and allocated to training and validation sets (7:3 ratio). Radiomics features were extracted from arterial and venous phase iodine maps, respectively. Radiomics signature was constructed based on reproducible features using the least absolute shrinkage and selection operator (LASSO) logistic regression algorithm with 10-fold cross-validation. Logistic regression modeling was employed to build models based on CT image features (model 1), radiomics signature (model 2), and the combined (model 3). A nomogram was plotted for the combined model and decision curve analysis was applied for clinical use. Diagnostic performance was assessed and compared. Internal validation was performed on an independent set containing 78 LNs. Model 3 showed optimal diagnostic performance in both training (AUC = 0.933) and validation set (AUC = 0.895), followed by model 2 (training set, AUC = 0.910; validation set, AUC = 0.847). Both these two models outperformed model 1 in both training (AUC = 0.763) (p < 0.05) and validation set (AUC = 0.728) (p < 0.05). Radiomics analysis of DECT-derived iodine maps showed better diagnostic performance than qualitative evaluation of CT image features in preoperative diagnosing cervical LN metastasis in PTC patients. Radiomics signature integrated with CT image features can serve as a promising imaging biomarker for the differentiation. • Conventional CT image features have limited value for the diagnosis of metastatic LNs in PTC patients. • Radiomics analysis of dual-energy CT-derived iodine maps significantly outperformed qualitative CT image features in differentiating metastatic from non-metastatic LNs. • Radiomics signature integrated with qualitative CT image features can serve as a useful tool in judging LNs status, thus aiding clinical decision-making.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have